An inhibitor that targets a specific mutation in relapsed or refractory acute myeloid leukaemia improves the survival rate of patients, a major conference has been told.
The phase III ADMIRAL trial, led by a team at the Abramson Cancer Center of the University of Pennsylvania, USA, has revealed that patients with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene lived twice as long if they took gilteritinib (a FLT3 inhibitor), compared to those who received chemotherapy.
Dr Alexander Perl, who presented the findings at the 2019 American Association for Cancer Research Annual Meeting in Atlanta, Georgia, USA, said “patients with FLT3 mutations who have relapsed or refractory AML have very low response rates to che...
12 days ago
An inhibitor that targets a specific mutation in relapsed or refractory acute myeloid leukaemia improves the survival rate of patients, a major conference has been told.
The phase III ADMIRAL trial, led by a team at the Abramson...
12 days ago
Researchers investigating acute erythroid leukaemia have identified five sub-groups of the condition that have distinct gene mutations and patient outcomes.
The diagnostic criteria for acute erythroid leukaemia have changed over...
12 days ago